QGEN - Diagnostic Firm Qiagen's Q3 Earnings: Analyst Says Annual Projections Attainable Despite Macro Trends | Benzinga

Qiagen NV's (NASDAQ: QGEN) Q3 net sales of $470 million at constant exchange rates (CER) for Q3 2023 were above the outlook for at least $465 million CER, driven by 5% CER growth in the non-COVID-19 portfolio. 

Overall sales results for Q3 2023 declined 5% (-6% CER) to $476 million from Q3 2022, a period marked by significant COVID-19 sales contributions. Adjusted EPS was $0.50, beating the consensus of $0.48.

Qiagen CEO Thierry Bernard said the firm's resilient performance "was important as we work through the final quarters of COVID-19 testing headwinds from 2022 and also address an increasingly challenging macro environment."

Also Read: Full story available on Benzinga.com